Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 14/20 | 0.56 |
| ▸ | TYMS | P04818 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 3/20 | 0.45 |
| ▸ | DPYD | Q12882 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26232174 | 0.81 | CHUK (0.49) | CHUKLRRK2IKBKBDPYD | |
| SCHEMBL18520454 | 0.76 | DYRK1A (0.47) | TYMS | |
| SCHEMBL15061831 | 0.75 | TYMS (0.48) | TYMS | |
| SCHEMBL12820951 | 0.75 | DYRK1A (0.46) | TYMS | |
| SCHEMBL12884842 | 0.75 | TYMS (0.46) | TYMS | |
| SCHEMBL24704369 | 0.75 | DYRK1A (0.46) | TYMS | |
| SCHEMBL21161374 | 0.72 | TYMS (0.49) | TYMS | |
| SCHEMBL166747 | 0.72 | TYMS (0.49) | TYMS | |
| SCHEMBL2261493 | 0.72 | TYMS (0.55) | TYMS | |
| SCHEMBL6311834 | 0.71 | CHUK (0.71) | CHUKIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 689 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339475-A1 | HEPATOPROTECTIVE PROBIOTIC COMPOSITIONS | UNIV TEXAS (US) | 2025-11-06 | — | — | US | claimed |
| EP-4600362-A1 | REPORTER GENE CONSTRUCT SENSITIVE TO QUEUOSINE LEVELS | Instituto Nacional de Técnica Aeroespacial "Esteban Terradas" (ES) | 2025-08-13 | — | — | EP | claimed |
| WO-2025075256-A1 | APPARATUS AND METHOD FOR EARLY DISEASE DETECTION BASED ON HIGH-DEPTH CELL-FREE NUCLEIC ACID SEQUENCING | (주)지놈포미 | 2025-04-10 | — | — | WO | claimed |
| US-20250019719-A1 | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2025-01-16 | — | — | US | claimed |
| WO-2024102452-A1 | HEPATOPROTECTIVE PROBIOTIC COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-16 | — | — | WO | claimed |
| CN-113881728-B | Preparation method of 7-aminomethyl-7-deazaguanine (PreQ 1) | 深圳瑞德林生物技术有限公司 | 2023-12-15 | — | — | CN | claimed |
| US-20220145308-A1 | MATERIALS AND METHODS FOR REDUCING NUCLEIC ACID DEGRADATION IN BACTERIA | NATIONAL INSTITUTES OF HEALTH | 2022-05-12 | — | — | US | claimed |
| US-20220096574-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING CENTRAL NERVOUS SYSTEM DISORDERS AND OTHER CONDITIONS CAUSED BY GUT MICROBIAL DYSBIOSIS | HOLOBIOME, INC. (US) | 2022-03-31 | — | — | US | claimed |
| WO-2021030666-A1 | BASE EDITING BY TRANSGLYCOSYLATION | THE BROAD INSTITUTE, INC. (US) | 2021-02-18 | — | — | WO | claimed |
| WO-2020185775-A2 | MATERIALS AND METHODS FOR REDUCING NUCLEIC ACID DEGRADATION IN BACTERIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-09-17 | — | — | WO | claimed |
| US-20260146262-A1 | METHODS OF LIPID NANOPARTICLE PRODUCTION IN CROSS-MIXERS | MODERNATX, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260137630-A1 | COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS | THE TRUSTEES OF THE UNIV OF PENNSYLVANIA (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | MODERNATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | ADVANCED RNA VACCINE ARV TECH INC (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2008116223-A1 | PREQ1 RIBOSWITCHES AND METHODS AND COMPOSITIONS FOR USE OF AND WITH PREQ1 RIBOSWITCHES | YALE UNIVERSITY (US) | 2008-09-25 | — | — | WO | disclosed |
| US-7364882-B1 | Enzymatic reduction of a nitrile containing compound to the corresponding amine | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2008-04-29 | — | — | US | disclosed |
| EP-0075881-B1 | 7-DEAZAPURINE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 1985-02-13 | — | — | EP | disclosed |
| US-4435570-A | ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
| EP-0075881-A1 | 7-Deazapurine derivatives | Takeda Chemical Industries, Ltd. (JP) | 1983-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137630-A1 | COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS | LCP2, CD47, CD4 | CHUK 2653/4885TYMS 2571/4885LRRK2 3659/4885 |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | RNMT, RNGTT, METTL16 | CHUK 4431/4885TYMS 677/4885LRRK2 3091/4885 |
| US-20220096574-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING CENTRAL NERVOUS SYSTEM DISORDERS AND OTHER CONDITIONS CAUSED BY GUT MICROBIAL DYSBIOSIS | TPH2, TPH1, HNMT | CHUK 4587/4885TYMS 1256/4885LRRK2 3760/4885 |
| US-20260146262-A1 | METHODS OF LIPID NANOPARTICLE PRODUCTION IN CROSS-MIXERS | ELAVL1, IGF2BP2, FUS | CHUK 3232/4885TYMS 3862/4885LRRK2 2246/4885 |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | TNFRSF9, CD40, TNFSF11 | CHUK 2368/4885TYMS 2098/4885LRRK2 1122/4885 |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | UPF1, NSUN2, CD4 | CHUK 3044/4885TYMS 1256/4885LRRK2 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.